Psychedelic Medicine

Association

Psychedelic

Medicine

Association
Sign in
Sign up

Integrating Psychedelic Clinical Trials into Your Practice

Log in to Watch the Recording

*Exclusive for members.

Tuesday, April 28th at 5 pm Pacific, 8 pm Eastern

An EXCLUSIVE Panel Discussion for Members of the Psychedelic Medicine Association:

Integrating Psychedelic Clinical Trials into Your Practice

Host:

Lynn Marie Morski, MD, JD

Lynn Marie Morski, MD, JD

President, Psychedelic Medicine Association

Panelists:

Manoj Doss, DO

Manoj Doss, DO

Founder & CEO, Institute for Integrative Therapies (IIT)

Dr. Manoj Doss, DO, MPA, MUSA is a board-certified physician in Addiction Medicine, and the Founder & CEO of the Institute for Integrative Therapies (IIT), Minnesota’s first psychedelic medicine clinic. He is among a small group of physicians in the United States who have successfully integrated psychedelic clinical research into routine clinical practice.

Dr. Doss serves as an investigator on multiple psychedelic clinical trials, including studies with COMPASS Pathways, Cybin, and atai Beckley. His work focuses on trial implementation, patient safety, protocol adherence, and translating research into real-world clinical care for conditions such as treatment-resistant depression and addiction.

At IIT, he has developed clinical workflows that integrate interventional psychiatry with research operations, creating a scalable model for delivering both care and clinical trials within the same practice. His work includes building site infrastructure, optimizing patient recruitment, and aligning clinical teams with Good Clinical Practice (GCP) standards.

Dr. Doss also consults with healthcare organizations on how to incorporate psychedelic research into their practices. He is a co-founder of INCREMENTAL, a platform designed to help clinics develop sustainable research pipelines, navigate sponsor relationships, and operationalize clinical trials within existing care models.

His work is focused on helping clinicians bridge the gap between emerging psychedelic research and everyday clinical practice.

William Sauvé, MD

William Sauvé, MD

Chief Medical Officer, Osmind

William Sauvé, MD is Chief Medical Officer at Osmind, where he focuses on driving the success of Osmind’s nationwide network of 800+ independent psychiatry practices and expanding access to cutting-edge psychiatric care.
‍
Dr. Sauvé brings extensive experience in interventional psychiatry, particularly in expanding access to treatments like Transcranial Magnetic Stimulation (TMS) and esketamine. Prior to joining Osmind, he served as Regional Medical Director for Greenbrook TMS NeuroHealth Centers, where he helped grow the organization's network to nearly 200 dedicated interventional psychiatry centers nationwide.
‍
His journey in psychiatry began with 11 years of distinguished service as an active-duty Navy psychiatrist. Following his residency, he was deployed to Iraq's Al Anbar Province as the regimental psychiatrist for the 7th Marine Regiment. During his time in the military, he started a procedural psychiatry program that included ECT and patient engagement in post-traumatic stress disorder (PTSD) treatment. 
‍
After his military service, he served as Military Clinical Director at Poplar Springs Hospital for three years before founding Virginia Interventional Psychiatry, one of the first interventional psychiatry practices in the Mid-Atlantic region. His practice, dedicated to advancing TMS treatment, was the first practice acquired into what is now Greenbrook TMS NeuroHealth Centers, contributing to their nationwide expansion in providing TMS and esketamine treatments.
‍
Dr. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He completed his residency in adult psychiatry through the National Capital Consortium, which includes the Walter Reed National Military Medical Center, Fort Belvoir Community Hospital, and USUHS. He earned his undergraduate degrees in Biology and Biochemistry from Mercyhurst College in Erie, Pennsylvania.
‍
He is certified by the American Board of Psychiatry and Neurology and serves as faculty at the Neuroscience Education Institute. He maintains an active membership in the American Psychiatric Association and the Clinical Transcranial Magnetic Stimulation Society.

Kayli Howard, MA

Licensed Psilocybin Facilitator, Marriage & Family Therapist Associate, Trainer Faculty for Fluence

Kayli Howard has a MA in Clinical Psychology from Antioch University, where she trained as a Marriage and Family Therapist. In 2023 she received certification in Psilocybin-Assisted Therapy through Fluence. She is one of Oregon’s first licensed psilocybin facilitators. Since receiving licensure she has guided nearly 150 legal psychedelic journeys and was awarded the “Clients' Choice” in Althea's Psilocybin Outcome Awards. She trains upcoming psychedelic facilitators as a faculty member of Fluence’s Colorado Natural Medicine program.

Reid Robison, MD, MBA

Chief Medical Officer at Novamind/Co-founder at Cedar Psychiatry

Dr. Reid Robison is a board-certified psychiatrist and Chief Medical Officer at Novamind. Reid is co-founder at Cedar Psychiatry and serves as Medical Director of Center for Change, a top Eating Disorder program. He is currently the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. Reid is adjunct faculty at the University of Utah, founder of the Polizzi Free Clinic, and provides medical support and psychedelic therapy at plant medicine retreats abroad.

As psychedelic research continues to expand, an increasing number of clinicians are asking a more concrete question:

What would it actually take to run a psychedelic clinical trial at my own practice?

Beyond referring patients or staying informed, there is a growing opportunity for clinicians to serve as study sites, bringing cutting-edge research directly into their existing clinical settings. But doing so involves navigating operational, regulatory, and clinical considerations that are not always straightforward.

From site selection and infrastructure to staffing, training, and patient flow, understanding what’s required to host a trial is essential for any practitioner considering deeper involvement in this space.

This webinar will provide a practical look at how clinicians can move from interest to implementation: what’s involved, what’s expected, and how to begin.

In this webinar, our panelists will cover:

  • The basic requirements to become a study site

  • Infrastructure, staffing, and training considerations

  • Patient recruitment and workflow within a clinical practice

  • Regulatory, ethical, and safety considerations

… and much more!

As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!

So please join us for this live panel discussion on Tuesday, April 28th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterward if you cannot make it to the live event.

You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.